Literature DB >> 11881109

Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension.

A Sonmez1, U Kisa, G Uckaya, T Eyileten, B Comert, B Koc, F Kocabalkan, M Ozata.   

Abstract

Recent evidence shows that leptin may contribute to elevated blood pressure (BP) and interact with the renin-angiotensin-aldosterone and cellular immune systems. Altered T-cell activities and changes in T-cell subset ratios have also been reported in hypertension. However, little is known about the effects of AT1-receptor antagonism on T-cell activities and plasma leptin concentrations in primary hypertension. We have, therefore, investigated the relationship between leptin and T-cell activities and the effect of an AT1-receptor antagonist, losartan, in primary hypertension. Twenty recently-diagnosed and untreated young adults (11 males and 9 females, age; 39.9+/-7.6 years, range 23-49 years, BMI; 27.6+/-3.7kg/m2) and 20 normotensive healthy, age-, sex- and BMI-matched controls were studied. The [3H]-thymidine uptakes of cultured lymphocytes were determined, both spontaneously and after stimulation with phytohaemagglutinin. The tests were performed before and after three months of treatment with losartan. The results indicate that the blastogenic responses of T-cells to phytohaemagglutinin are significantly higher in the patient group compared with controls (p=0.02). After normalisation of BP, T-cell responses were significantly reduced and were lower than in the controls (p=0.01). Pretreatment plasma leptin levels were significantly higher in hypertensives than in controls (p=0.01). However, losartan treatment had no significant effect on leptin concentrations; moreover, no correlation between leptin levels and T-cell activity was found. Our data show that plasma leptin levels and T-cell activity are markedly enhanced in untreated essential hypertension and that the alteration of T-cell activity is not related to plasma leptin levels. Antihypertensive treatment with losartan decreases T-cell activities but does not influence plasma leptin levels. We conclude that leptin levels are not affected by AT1-receptor blockade and are not related to T-cell activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11881109     DOI: 10.3317/jraas.2001.011

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  11 in total

Review 1.  Immunologic Effects of the Renin-Angiotensin System.

Authors:  Steven D Crowley; Nathan P Rudemiller
Journal:  J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 10.121

Review 2.  Leptin and cardiovascular disease: response to therapeutic interventions.

Authors:  Kwang Kon Koh; Sang Min Park; Michael J Quon
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

Review 3.  Sex differences in T cells in hypertension.

Authors:  Ashlee J Tipton; Jennifer C Sullivan
Journal:  Clin Ther       Date:  2014-08-16       Impact factor: 3.393

Review 4.  T-cell involvement in sex differences in blood pressure control.

Authors:  G Ryan Crislip; Jennifer C Sullivan
Journal:  Clin Sci (Lond)       Date:  2016-05-01       Impact factor: 6.124

5.  Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1.

Authors:  Shu-Meng Cheng; Shih-Ping Yang; Ling-Jun Ho; Tien-Ping Tsao; Deh-Ming Chang; Jenn-Haung Lai
Journal:  Br J Pharmacol       Date:  2004-06-21       Impact factor: 8.739

Review 6.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

Review 7.  Leptin and hypertension in obesity.

Authors:  Paco E Bravo; Stephen Morse; David M Borne; Erwin A Aguilar; Efrain Reisin
Journal:  Vasc Health Risk Manag       Date:  2006

8.  Dysfunction of the thymus in mice with hypertension.

Authors:  Xianliang Dai; Shuaibo Huang; Zhiqing He; Feng Wu; Ru Ding; Yihong Chen; Chun Liang; Zonggui Wu
Journal:  Exp Ther Med       Date:  2017-02-15       Impact factor: 2.447

9.  Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts.

Authors:  Sandra M Cockfield; Sam Wilson; Patricia M Campbell; Marcelo Cantarovich; Azim Gangji; Isabelle Houde; Anthony M Jevnikar; Tammy M Keough-Ryan; Felix-Mauricio Monroy-Cuadros; Peter W Nickerson; Michel R Pâquet; G V Ramesh Prasad; Lynne Senécal; Ahmed Shoker; Jean-Luc Wolff; John Howell; Jason J Schwartz; David N Rush
Journal:  Am J Transplant       Date:  2019-02-01       Impact factor: 8.086

10.  Drug Repurposing for COVID-19 using Graph Neural Network with Genetic, Mechanistic, and Epidemiological Validation.

Authors:  Kang-Lin Hsieh; Yinyin Wang; Luyao Chen; Zhongming Zhao; Sean Savitz; Xiaoqian Jiang; Jing Tang; Yejin Kim
Journal:  Res Sq       Date:  2020-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.